Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBITDA (2016 - 2025)

Amicus Therapeutics' EBITDA history spans 16 years, with the latest figure at $15.9 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA changed 0.16% year-over-year to $15.9 million, compared with a TTM value of $32.8 million through Dec 2025, up 31.81%, and an annual FY2025 reading of $36.7 million, up 22.8% over the prior year.
  • EBITDA for Q4 2025 was $15.9 million at Amicus Therapeutics, down from $34.3 million in the prior quarter.
  • The five-year high for EBITDA was $34.3 million in Q3 2025, with the low at -$75.3 million in Q1 2022.
  • Average EBITDA over 5 years is -$21.9 million, with a median of -$23.3 million recorded in 2023.
  • Year-over-year, EBITDA surged 532.58% in 2024 and then crashed 163.3% in 2025.
  • Tracing FOLD's EBITDA over 5 years: stood at -$72.1 million in 2021, then surged by 41.33% to -$42.3 million in 2022, then soared by 91.28% to -$3.7 million in 2023, then surged by 532.58% to $16.0 million in 2024, then dropped by 0.16% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's EBITDA are $15.9 million (Q4 2025), $34.3 million (Q3 2025), and -$9.5 million (Q2 2025).